Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty math, Captisol shipment volumes, and partner milestone clauses turn each Ligand Pharmaceuticals filing into a maze of tables and footnotes. If you have ever searched hundreds of pages just to confirm which partner drove last quarter鈥檚 royalty surge, you know the challenge. Stock Titan solves this complexity by turning every Ligand disclosure鈥攆rom the latest 8-K material event to its 250-page annual report鈥攊nto concise insights you can act on.
Our platform ingests every document the moment it hits EDGAR and generates AI-powered summaries that explain the impact in plain English. Need the numbers behind the "Ligand Pharmaceuticals quarterly earnings report 10-Q filing"? We tag segment revenue, cash-flow swings, and Captisol sales automatically. Monitoring executives? Receive real-time alerts for "Ligand Pharmaceuticals insider trading Form 4 transactions" and spot buying or selling patterns before the market digests them. Whether you are comparing pipeline milestones across 10-K sections or verifying "Ligand Pharmaceuticals proxy statement executive compensation" details, the information is organized, searchable, and translated into clear language.
Here鈥檚 what you gain: instant context around royalty forecasts, AI commentary that demystifies complex licensing disclosures, and full coverage of every form鈥�10-K, 10-Q, 8-K, S-8, and Form 4鈥攄elivered the moment Ligand files. Skip the manual page-flip: with Stock Titan you鈥檙e "understanding Ligand Pharmaceuticals SEC documents with AI" in minutes, tracking "Ligand Pharmaceuticals executive stock transactions Form 4" effortlessly, and turning dense reports into strategic decisions without losing valuable time.
Ligand Pharmaceuticals reported a proposed private placement of $400.0 million aggregate principal amount of convertible senior notes due 2030, with initial purchasers offered a 13-day option to buy up to an additional $60.0 million. The notes are being offered to qualified institutional buyers under Rule 144A and have not been registered under the Securities Act.
The company also entered into a Second Amendment to its Credit Agreement to permit certain cash settlement payments on the notes, subject to customary conditions. The filing includes the amendment and a press release as exhibits, and emphasizes that any offering will be made only by confidential offering memorandum and is not a public solicitation.
Ligand Pharmaceuticals (LGND) reported stronger results in the quarter ended June 30, 2025, with total revenues of $47.6 million, up from $41.5 million a year earlier, driven by higher royalties of $36.4 million and a jump in income from financial royalty assets to $6.3 million from $0.6 million. Operating income for the quarter turned positive at $8.4 million compared with an operating loss a year earlier, reflecting higher royalty receipts and Captisol sales.
Despite the quarterly improvement, the first half of 2025 produced a $51.9 million net loss versus net income of $34.2 million in the prior-year period, largely reflecting non-operating swings and a $44.3 million one-time research and development expense tied to the Castle Creek transaction. Material transactions this period include the Castle Creek investment (Ligand funded $50 million of a $75 million syndicate, allocating $44.3 million to D-Fi royalty rights and $5.8 million to a warrant) and the prior Apeiron acquisition (base consideration $100.5 million with Qarziba royalty assets added). Balance sheet highlights: total assets $948.6 million, cash $67.7 million, and stockholders' equity $828.5 million; Pelthos was classified as held for sale with assets of $35.2 million and related liabilities of $35.7 million.
Ligand Pharmaceuticals (LGND) 鈥� Form 4 filing: Chief Financial Officer Octavio Espinoza acquired 224 common shares on 30 June 2025 through the company鈥檚 Employee Stock Purchase Plan (ESPP), a transaction coded 鈥淛,鈥� which is exempt under Rules 16b-3(c) and 16b-3(d).
The shares were purchased at an average price of $91.08 per share, increasing Espinoza鈥檚 direct beneficial ownership to 29,852 shares. No derivative securities were reported in Table II. The filing was signed on 2 July 2025 by an attorney-in-fact on behalf of the executive.
Because the purchase occurred under an automatic ESPP rather than an open-market discretionary trade, the signal for insider sentiment is modest; however, it still marginally aligns executive and shareholder interests.
FAQ
What is the current stock price of Ligand Pharma (LGND)?
What is the market cap of Ligand Pharma (LGND)?
